<DOC>
	<DOCNO>NCT01676987</DOCNO>
	<brief_summary>To evaluate efficacy safety fixed-dose , single-capsule budesonide ( 400µg ) -formoterol ( 12µg ) combination , comparison budesonide alone , deliver via dry powder inhaler , 181 patient uncontrolled asthma.This Randomized , double-blind , multicenter , phase III , parallel clinical trial .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Fixed-dose , Single-capsule Budesonide-formoterol Combination Uncontrolled Asthma</brief_title>
	<detailed_description>age patient range 18 77 year . After run-in period 4 week , patient receive budesonide twice day , randomize one treatment group 12 week , twice day . The primary outcome measure FEV1 , FVC morning PEF . We perform intention-to-treat analysis data .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Adrenergic beta-2 Receptor Agonists</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Diagnosis uncontrolled asthma Age range 18 77 year Nonsmokers Use oral corticosteroid , antileukotrienes , immunoglobulin , beta blocker , digitalis , amiodarone , antifungal , antidepressant , monoamine oxidase inhibitor tricyclic standardization Atrial fibrillation , Flutter , severe complex tachyarrhythmias atrioventricular block 1,2 3 Diabetes mellitus Pregnancy Neuropsychiatric diseases Pulmonary malformation , tuberculosis , Cystic fibrosis Immunosuppressive treatment Hospitalization asthma respiratory infection last 30 day Severe systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Adrenergic beta-2 receptor agonist .</keyword>
</DOC>